BioRestorative Therapies (BRTX) 10-Q 13 May 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 11, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1,505,497
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	BRTX
Entity Common Stock, Shares Outstanding		3,993,068

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current Assets:
Cash	$ 353,095	$ 166,555
Accounts receivable	9,000	93,375
Prepaid expenses and other current assets	22,060	29,348
Total Current Assets	384,155	289,278
Property and equipment, net	599,419	643,087
Intangible assets, net	1,020,017	1,038,741
Security deposit	45,900	45,900
Total Assets	2,049,491	2,017,006
Current Liabilities:
Accounts payable	2,194,086	2,549,042
Accrued expenses and other current liabilities	2,044,649	2,046,795
Accrued interest	34,586	6,823
Current portion of notes payable, net of debt discount of $64,803 and $150,286 at March 31, 2016 and December 31, 2015, respectively	1,316,780	1,009,797
Total Current Liabilities	5,590,101	5,612,457
Accrued interest, non-current portion	0	11,011
Notes payable, non-current portion, net of debt discount of $0 and $7,999 at March 31, 2016 and December 31, 2015, respectively	0	302,001
Total Liabilities	$ 5,590,101	$ 5,925,469
Commitments and contingencies
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 5,000,000 shares; none issued and outstanding at March 31, 2016 and December 31, 2015	$ 0	$ 0
Common stock, $0.001 par value; Authorized, 30,000,000 shares; Issued 3,958,750 and 3,338,661 shares at March 31, 2016 and December 31 2015, respectively; Outstanding 3,930,818 and 3,310,729 shares at March 31, 2016 and December 31, 2015, respectively	3,959	3,339
Additional paid-in capital	32,298,265	29,443,704
Accumulated deficit	(35,810,834)	(33,323,506)
Treasury stock, at cost, 27,932 shares at March 31, 2016 and December 31, 2015	(32,000)	(32,000)
Total Stockholders' Deficiency	(3,540,610)	(3,908,463)
Total Liabilities and Stockholders' Deficiency	$ 2,049,491	$ 2,017,006

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current portion of notes payable, debt discount (in dollars)	$ 64,803	$ 150,286
Non-current portion of notes payable, debt discount (in dollars)	$ 0	$ 7,999
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, Authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, Authorized	30,000,000	30,000,000
Common stock, Issued	3,958,750	3,338,661
Common stock, Outstanding	3,930,818	3,310,729
Treasury stock, at cost, shares	27,932	27,932

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues	$ 9,125	$ 184,902
Cost of sales	10	76,432
Gross Profit	9,115	108,470
Operating Expenses
Marketing and promotion	22,517	44,937
Consulting	284,807	365,069
Research and development	866,044	406,856
General and administrative	902,881	917,574
Total Operating Expenses	2,076,249	1,734,436
Loss From Operations	(2,067,134)	(1,625,966)
Other Expense
Interest expense	(42,840)	(64,640)
Amortization of debt discount	(337,021)	(69,515)
Loss on extinguishment of notes payable, net	(11,847)	0
Warrant modification expense	(28,486)	0
Total Other Expense	(420,194)	(134,155)
Net Loss	$ (2,487,328)	$ (1,760,121)
Net Loss Per Share
- Basic and Diluted (in dollars per share)	$ (0.69)	$ (1)
Weighted Average Number of Common Shares Outstanding
Basic and Diluted (in shares)	3,619,813	1,755,398

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) - 3 months ended Mar. 31, 2016 - USD ($)	Total	Common Stock	Additional paid-in capital	Accumulated deficit	Treasury Stock
Beginning Balance at Dec. 31, 2015	$ (3,908,463)	$ 3,339	$ 29,443,704	$ (33,323,506)	$ (32,000)
Beginning Balance (in shares) at Dec. 31, 2015		3,338,661			(27,932)
Shares and warrants issued for cash	1,618,372	$ 405	1,617,967	0	$ 0
Shares and warrants issued for cash (in shares)		404,593			0
Exercise of warrants for purchase of common stock	212,898	$ 61	212,837	0	$ 0
Exercise of warrants for purchase of common stock (in shares)		60,831			0
Conversion of notes payable and accrued interest into common stock	157,370	$ 52	157,318	0	$ 0
Conversion of notes payable and accrued interest into common stock (in shares)		52,457			0
Shares issued in satisfaction of accrued services	2,333	$ 1	2,332	0	$ 0
Shares issued in satisfaction of accrued services (in shares)		753			0
Warrants issued as debt discount in connection with notes payable	31,009	$ 0	31,009	0	$ 0
Warrants issued as debt discount in connection with notes payable (in shares)		0			0
Shares and warrants issued in exchange of note payable and accrued interest	177,649	$ 79	177,570	0	$ 0
Shares and warrants issued in exchange of note payable and accrued interest (in shares)		78,955			0
Warrant modifications	28,486	$ 0	28,486	0	$ 0
Beneficial conversion features related to convertible notes payable	215,446	0	215,446	0	0
Stock-based compensation: - common stock	50,624	$ 22	50,602	0	$ 0
Stock-based compensation: - common stock (in shares)		22,500			0
Stock-based compensation: - options and warrants	360,994	$ 0	360,994	0	$ 0
Stock-based compensation: - options and warrants (in shares)		0			0
Net loss	(2,487,328)	$ 0	0	(2,487,328)	$ 0
Ending Balance at Mar. 31, 2016	$ (3,540,610)	$ 3,959	$ 32,298,265	$ (35,810,834)	$ (32,000)
Ending Balance (in shares) at Mar. 31, 2016		3,958,750			(27,932)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows From Operating Activities
Net loss	$ (2,487,328)	$ (1,760,121)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	337,021	69,515
Accretion of interest expense	2,916	0
Depreciation and amortization	62,392	39,613
Stock-based compensation	411,618	371,167
Loss on extinguishment of note payables, net	11,847	0
Warrant modification expense	28,486	0
Changes in operating assets and liabilities:
Accounts receivable	84,375	0
Prepaid expenses and other current assets	7,288	(11,850)
Security deposit	0	0
Accounts payable	(265,091)	80,534
Accrued interest, expenses and other current liabilities	88,641	489,831
Deferred revenues	0	46,533
Total Adjustments	769,493	1,085,343
Net Cash Used In Operating Activities	(1,717,835)	(674,778)
Cash Flows From Investing Activities
Purchases of property and equipment	(89,865)	(92,169)
License maintenance costs	0	(75,000)
Net Cash Used In Investing Activities	(89,865)	(167,169)
Cash Flows From Financing Activities
Proceeds from notes payable	325,000	30,000
Repayments of notes payable	(103,500)	0
Advances from an officer	46,030	125,070
Repayments of advances from an officer and a director	(104,560)	(60,055)
Proceeds from exercise of warrants	212,898	0
Sales of common stock and warrants for cash	1,618,372	801,000
Net Cash Provided By Financing Activities	1,994,240	896,015
Net Increase In Cash	186,540	54,068
Cash - Beginning	166,555	91,798
Cash - Ending	353,095	145,866
Cash paid during the period for:
Interest	10,000	36,540
Non-cash investing and financing activities:
Conversion of notes payable and accrued interest into common stock	157,370	55,984
Beneficial conversion features set up as debt discount	215,446	10,690
Accrued liabilities associated with purchases of property and equipment	0	64,276
Warrant modifications in connection with extension of notes payable and setup as debt discount
Non-cash investing and financing activities:
Stock Issued	0	5,900
Shares and warrants issued in connection with issuance or extension of notes payable
Non-cash investing and financing activities:
Stock Issued	31,009	0
Shares and warrants issued in exchange for notes payable and accrued interest
Non-cash investing and financing activities:
Stock Issued	177,649	0
Shares issued in satisfaction of accrued consulting services
Non-cash investing and financing activities:
Stock Issued	$ 2,333	$ 8,481

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	Note 1 – Business Organization, Nature of Operations and Basis of Presentation BioRestorative Therapies, Inc. has two wholly-owned subsidiaries, Stem Pearls, LLC (“Stem Pearls”) and Stem Cell Cayman Ltd. (“Cayman”), which was formed in the Cayman Islands (collectively, “BRT” or the “Company”). BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com www.stempearls.com The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of March 31, 2016 and for the three months ended March 31, 2016 and 2015. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the operating results for the full year ending December 31, 2016 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2015 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on March 30, 2016. Effective July 7, 2015, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-20 reverse split 200,000,000 30,000,000

Going Concern and Management's

Going Concern and Management's Plans	3 Months Ended
	Mar. 31, 2016
Development Stage Enterprise [Abstract]
Going Concern and Management Plans	Note 2 – Going Concern and Management’s Plans As of March 31, 2016, the Company had a working capital deficiency and a stockholders’ deficiency of $ 5,205,946 3,540,610 2,487,328 1,760,121 The Company's primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Subsequent to March 31, 2016, we have received aggregate equity financing (including proceeds from the exercise of common stock purchase warrants) and debt financing of $ 225,000 155,000 148,000 15,000 346,518

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies The unaudited condensed consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three months ended March 31, 2015. See Revenue Recognition – Research and Development Agreements below. Research and Development Agreements During the three months ended March 31, 2016 and 2015, the Company recognized revenue related to research and development agreements of $ 0 180,702 Other During the three months ended March 31, 2016 and 2015, the Company recognized $ 9,000 4,000 During the three months ended March 31, 2016 and 2015, the Company recognized revenue related to sales of Stem Pearls skincare products of $ 125 200 Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. March 31, 2016 2015 Options 1,345,450 809,200 Warrants 2,275,036 454,976 Convertible notes 68,467 33,941 Total potentially dilutive shares 3,688,953 1,298,117 The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements, except as disclosed. In March 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation – Stock Compensation (Topic 718)” (“ASU 2016-09”). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company is currently evaluating ASU 2016-09 and its impact on its financial statements or disclosures.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2016
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities March 31, December 31, 2016 2015 (unaudited) Credit card payable $ 2,737 $ 3,171 Accrued payroll 984,287 1,010,633 Advances from related parties 28,500 87,030 Accrued research and development expenses 476,175 446,175 Accrued general and administrative expenses 509,495 456,182 Deferred rent 43,455 43,604 Total $ 2,044,649 $ 2,046,795 During the three months ended March 31, 2016, the Company received an aggregate of $ 46,030 104,560 125,070 60,055

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2016
Notes Payable [Abstract]
Notes Payable	Note 5 – Notes Payable Bermuda Lender Convertible Other Debt (defined below) Notes Notes Discount Total Outstanding, December 31, 2015 $ 150,000 $ 420,000 [1] $ 900,083 $ (158,285) $ 1,311,798 Issuance - 75,000 250,000 - 325,000 Exchanges to equity - (160,000) - - (160,000) Conversion to equity - (150,000) - - (150,000) Repayments - - (103,500) - (103,500) Recognition of debt discount - - - (246,455) (246,455) Amortization of debt discount - - - 337,021 337,021 Accretion of interest expense - - - 2,916 2,916 Outstanding, March 31, 2016 $ 150,000 $ 185,000 [1] $ 1,046,583 $ (64,803) $ 1,316,780 [1] As of March 31, 2016 and December 31, 2015, convertible notes with an aggregate principal balance of $ 185,000 420,000 132,500 197,500 Bermuda Lender As of March 31, 2016, a lender (the “Bermuda Lender”) is a related party as a result of the size of its ownership interest in the Company's common stock. Convertible Notes and Other Notes Issuances On February 18, 2016, the Company issued a one-year other note payable with a principal amount of $ 250,000 10 20,000 4.00 31,009 On March 7, 2016, the Company issued a convertible note with a principal amount of $ 75,000 10 25,000 25,000 25,000 (a) 62% of the fair market value of the Company’s stock or (b) $2.00 per share. Should the Company elect to convert any of the note principal and respective accrued interest, the holder will have the right to accelerate the conversion of the remaining outstanding principal and accrued interest of the note. Conversions, Exchanges and Other Between January 26, 2016 and February 18, 2016, the Company elected to convert certain convertible notes with an aggregate principal balance of $ 150,000 7,370 52,457 3.00 During the three months ended March 31, 2016, the Company and a certain lender agreed to exchange certain other notes with an aggregate principal balance of $ 160,000 5,802 78,955 2.10 177,649 11,847 On February 15, 2016, the Company and a lender agreed to extend the maturity date of a non-interest bearing note payable in the original principal amount of $ 244,000 61,000 56,000 5,000 188,000 30,000 25,000 5,000 163,000 During the three months ended March 31, 2016 (excluding amounts repaid as discussed above) the Company repaid an aggregate principal amount of $ 22,500 During the three months ended March 31, 2016, the contingently adjustable conversion ratio associated with certain convertible notes was resolved and such notes became convertible during the period. The Company estimated the intrinsic value of the embedded conversion option based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the convertible note. During the three months ended March 31, 2016 and 2015, the Company recognized $ 215,446 10,690

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies Operating Lease Rent expense amounted to $ 33,000 35,000 Employment Agreements During the three months ended March 31, 2016, the Company’s Compensation Committee and Board of Directors approved performance-based cash bonuses for the year ended December 31, 2016 for the Company’s officers and certain employees in the aggregate amount of up to $ 407,000 Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. In the opinion of management, such matters are currently The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

Stockholders' Deficiency

Stockholders' Deficiency	3 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders Equity Note Disclosure	Note 7 – Stockholders’ Deficiency Common Stock and Warrant Offerings During the three months ended March 31, 2016, the Company issued an aggregate of 404,593 1,248,937 4.50 5.00 1,618,372 444,444 400,000 404,493 0.7 1.0 5.0 1,127,283 Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate ranging from 0 5 Warrant Exercises During the three months ended March 31, 2016, warrants to purchase an aggregate of 60,831 3.50 4.00 15.00 212,898 23,448 Stock Warrants For The Three Months Ended March 31, 2016 2015 Risk free interest rate 0.44% - 1.47 % 1.22% - 1.61 % Expected term (years) 0.67 - 5.00 5.00 Expected volatility 124 % 122 % Expected dividends 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the three months ended March 31, 2016 and 2015 was approximately $ 0.89 3.20 470,085 15.00 4.00 5,038 The Company recorded no stock–based compensation expense during the three months ended March 31, 2016 and 2015 related to stock warrants issued as compensation. As of March 31, 2016, there was no unrecognized stock-based compensation expense related to stock warrants. Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, January 1, 2016 1,066,930 $ 7.56 [1] Compensatory grants - - Investor grants 1,268,937 4.81 Exercised (60,831) 3.50 Forfeited - - Outstanding, March 31, 2016 2,275,036 $ 5.85 [1] 3.7 $ 153,318 Exercisable, March 31, 2016 2,240,036 $ 5.85 3.7 $ 153,318 [1] Excludes the impact of a warrant to purchase 35,000 30.00 Stock Options Weighted Average Remaining For the Three Months Ended Unrecognized at Amortization March 31, March 31, Period 2016 2015 2016 (Years) Consulting $ 104,098 $ 96,803 $ 704,231 2.1 Research and development 107,183 128,432 686,464 2.0 General and administrative 149,713 69,285 893,287 2.0 $ 360,994 $ 294,520 $ 2,283,982 2.0 Compensatory Common Stock Issuances For The Three Months Ended Unrecognized at March 31, March 31, 2016 2015 2016 Consulting $ 50,624 $ 67,800 $ - Research and development - 8,847 - $ 50,624 $ 76,647 $ -

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 8 - Subsequent Events Common Stock and Warrant Offerings Subsequent to March 31, 2016, the Company issued an aggregate of 56,250 4.00 225,000 56,250 5.00 Short Term Advances Subsequent to March 31, 2016, the Company repaid an aggregate of $ 28,500 Notes Payable On April 27, 2016, the Company issued a one-year note payable in the principal amount of $ 90,000 10 10,000,000 10,000 4.00 On April 27, 2016, the Company issued a convertible note in the principal amount of $ 65,000 10 The convertible note is payable as follows: (i) $25,000 of the principal and the respective accrued interest on such principal is payable six months from the issuance date (the “First Maturity Date”), (ii) $20,000 of principal and the respective accrued interest on such principal is payable two weeks following the First Maturity Date, and (iii) $20,000 of principal and the respective accrued interest on such principal is payable one month following the First Maturity Date. Each tranche of principal and the respective accrued interest on such principal is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to each maturity date and ending on the day immediately prior to each maturity date at a conversion price equal to the greater of (a) 60% of the fair value of the Company’s stock or (b) $2.00 per share. five-year 7,500 4.00 Subsequent to March 31, 2016, the Company extended the maturity date of a note payable in the principal amount of $ 163,000 20,000 15,000 5,000 148,000 6,000

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Consolidation Policy	Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Concentration Risk Credit Risk	Concentrations and Credit Risk Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three months ended March 31, 2015. See Revenue Recognition – Research and Development Agreements below.
Revenue Recognition	Revenue Recognition Research and Development Agreements During the three months ended March 31, 2016 and 2015, the Company recognized revenue related to research and development agreements of $ 0 180,702 Other During the three months ended March 31, 2016 and 2015, the Company recognized $ 9,000 4,000 During the three months ended March 31, 2016 and 2015, the Company recognized revenue related to sales of Stem Pearls skincare products of $ 125 200
Earnings Per Share	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. March 31, 2016 2015 Options 1,345,450 809,200 Warrants 2,275,036 454,976 Convertible notes 68,467 33,941 Total potentially dilutive shares 3,688,953 1,298,117
Share Based Compensation Option and Incentive Plans Policy	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements, except as disclosed.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In March 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation – Stock Compensation (Topic 718)” (“ASU 2016-09”). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company is currently evaluating ASU 2016-09 and its impact on its financial statements or disclosures.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Schedule of Weighted Average Number of Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: March 31, 2016 2015 Options 1,345,450 809,200 Warrants 2,275,036 454,976 Convertible notes 68,467 33,941 Total potentially dilutive shares 3,688,953 1,298,117

Accrued Expenses and Other Cu17

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2016
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following: March 31, December 31, 2016 2015 (unaudited) Credit card payable $ 2,737 $ 3,171 Accrued payroll 984,287 1,010,633 Advances from related parties 28,500 87,030 Accrued research and development expenses 476,175 446,175 Accrued general and administrative expenses 509,495 456,182 Deferred rent 43,455 43,604 Total $ 2,044,649 $ 2,046,795

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2016
Notes Payable [Abstract]
Schedule of Debt	A summary of the notes payable activity during the three months ended March 31, 2016 is presented below: Bermuda Lender Convertible Other Debt (defined below) Notes Notes Discount Total Outstanding, December 31, 2015 $ 150,000 $ 420,000 [1] $ 900,083 $ (158,285) $ 1,311,798 Issuance - 75,000 250,000 - 325,000 Exchanges to equity - (160,000) - - (160,000) Conversion to equity - (150,000) - - (150,000) Repayments - - (103,500) - (103,500) Recognition of debt discount - - - (246,455) (246,455) Amortization of debt discount - - - 337,021 337,021 Accretion of interest expense - - - 2,916 2,916 Outstanding, March 31, 2016 $ 150,000 $ 185,000 [1] $ 1,046,583 $ (64,803) $ 1,316,780 [1] As of March 31, 2016 and December 31, 2015, convertible notes with an aggregate principal balance of $ 185,000 420,000 132,500 197,500

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	3 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Schedule Of Sharebased Payment Award Warrants Valuation Assumptions	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For The Three Months Ended March 31, 2016 2015 Risk free interest rate 0.44% - 1.47 % 1.22% - 1.61 % Expected term (years) 0.67 - 5.00 5.00 Expected volatility 124 % 122 % Expected dividends 0.00 % 0.00 %
Schedule Of Share Based Compensation Warrant Outstanding and Exercisable By Exercise Price Range	A summary of the warrant activity during the three months ended March 31, 2016 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, January 1, 2016 1,066,930 $ 7.56 [1] Compensatory grants - - Investor grants 1,268,937 4.81 Exercised (60,831) 3.50 Forfeited - - Outstanding, March 31, 2016 2,275,036 $ 5.85 [1] 3.7 $ 153,318 Exercisable, March 31, 2016 2,240,036 $ 5.85 3.7 $ 153,318 [1] Excludes the impact of a warrant to purchase 35,000 30.00
Schedule Of Stock Option Expense	The following table presents information related to stock option expense: Weighted Average Remaining For the Three Months Ended Unrecognized at Amortization March 31, March 31, Period 2016 2015 2016 (Years) Consulting $ 104,098 $ 96,803 $ 704,231 2.1 Research and development 107,183 128,432 686,464 2.0 General and administrative 149,713 69,285 893,287 2.0 $ 360,994 $ 294,520 $ 2,283,982 2.0
Common Stock Award Expense	The following table presents information related to compensatory common stock expense: For The Three Months Ended Unrecognized at March 31, March 31, 2016 2015 2016 Consulting $ 50,624 $ 67,800 $ - Research and development - 8,847 - $ 50,624 $ 76,647 $ -

Business Organization, Nature20

Business Organization, Nature of Operations and Basis of Presentation - Additional Information (Detail) - shares	Jul. 07, 2015	Mar. 31, 2016	Dec. 31, 2015
Business Organization and Nature Of Operations [Line Items]
Reverse stock split ratio	the Company implemented a 1-for-20 reverse split
Changes in capital structure retroactive impact shares	200,000,000
Common stock, authorized	30,000,000	30,000,000	30,000,000

Going Concern and Management'21

Going Concern and Management's Plans - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Working capital deficiency	$ 5,205,946
Stockholders deficiency	(3,540,610)		$ (3,908,463)
Net loss	(2,487,328)	$ (1,760,121)
Amount raised through equity financing	225,000
Notes payable aggregate principal past due	346,518
Proceeds From Debt Financing	155,000
Notes Payable	1,316,780		$ 1,311,798
Research and Development Arrangement [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Repayments of Debt	15,000
Notes Payable	$ 148,000

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	3,688,953	1,298,117
Options
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	1,345,450	809,200
Warrants
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	2,275,036	454,976
Convertible Notes
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	68,467	33,941

Summary of Significant Accoun23

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Revenues	$ 9,125	$ 184,902
Sublicense Agreement
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Revenue Recognized	9,000	4,000
Research and development agreements
Summary Of Significant Accounting Policies [Line Items]
Revenues	0	180,702
Stem Pearls Skincare Products
Summary Of Significant Accounting Policies [Line Items]
Revenues	$ 125	$ 200

Accrued Expenses and Other Cu24

Accrued Expenses and Other Current Liabilities (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Accrued Expenses and Other Current Liabilities [Line Items]
Credit card payable	$ 2,737	$ 3,171
Accrued payroll	984,287	1,010,633
Advances from related parties	28,500	87,030
Accrued research and development expenses	476,175	446,175
Accrued general and administrative expenses	509,495	456,182
Deferred rent	43,455	43,604
Total	$ 2,044,649	$ 2,046,795

Accrued Expenses and Other Cu25

Accrued Expenses and Other Current Liabilities - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Accrued Expenses and Other Current Liabilities [Line Items]
Advances from officer	$ 46,030	$ 125,070
Repayment of advances from officer	104,560	60,055
Non-Interest Bearing Advance [Member]
Accrued Expenses and Other Current Liabilities [Line Items]
Advances from officer	46,030	125,070
Repayment of advances from officer	$ 104,560	$ 60,055

Notes Payable (Detail)

Notes Payable (Detail) - USD ($)		3 Months Ended
		Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Outstanding		$ 1,311,798
Issuance		325,000
Exchanges to equity		(160,000)
Conversion to equity		(150,000)
Repayments		(103,500)	$ 0
Recognition of debt discount		(246,455)
Amortization of debt discount		337,021	69,515
Accretion of interest expense		2,916	$ 0
Outstanding		1,316,780
Debt Discount
Debt Instrument [Line Items]
Outstanding		(158,285)
Issuance		0
Exchanges to equity		0
Conversion to equity		0
Repayments		0
Recognition of debt discount		(246,455)
Amortization of debt discount		337,021
Accretion of interest expense		2,916
Outstanding		(64,803)
Bermuda Lender
Debt Instrument [Line Items]
Outstanding		150,000
Issuance		0
Exchanges to equity		0
Conversion to equity		0
Repayments		0
Recognition of debt discount		0
Amortization of debt discount		0
Accretion of interest expense		0
Outstanding		150,000
Convertible Notes
Debt Instrument [Line Items]
Outstanding	[1]	420,000
Issuance		75,000
Exchanges to equity		(160,000)
Conversion to equity		(150,000)
Repayments		0
Recognition of debt discount		0
Amortization of debt discount		0
Accretion of interest expense		0
Outstanding	[1]	185,000
Other Notes
Debt Instrument [Line Items]
Outstanding		900,083
Issuance		250,000
Exchanges to equity		0
Conversion to equity		0
Repayments		(103,500)
Recognition of debt discount		0
Amortization of debt discount		0
Accretion of interest expense		0
Outstanding		$ 1,046,583
[1]	As of March 31, 2016 and December 31, 2015, convertible notes with an aggregate principal balance of $185,000 and $420,000, respectively, become convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercises that conversion right on a designated portion of such principal balance, the holder has the right to accelerate the conversion of up to $132,500 and $197,500, respectively, of principal into shares of common stock.

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - USD ($)	Mar. 07, 2016	Mar. 04, 2016	Feb. 18, 2016	Feb. 15, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Debt Instrument [Line Items]
Aggregate principal amount		$ 30,000
Rate of interest	10.00%
Debt instrument, face amount	$ 75,000				$ 163,000
Loss on extinguishment of note payables, net					11,847	$ 0
Debt Instrument Periodic Payment Interest		5,000		$ 5,000
Debt Instrument, Periodic Payment, Principal		25,000		56,000
Debt Instrument, Convertible, Beneficial Conversion Feature					215,446	10,690
Debt Conversion, Original Debt, Amount		$ 188,000
Notes Payable, Noncurrent, Total					0		$ 302,001
Debt Instrument Conversion Period Description	(a) 62% of the fair market value of the Companys stock or (b) $2.00 per share. Should the Company elect to convert any of the note principal and respective accrued interest, the holder will have the right to accelerate the conversion of the remaining outstanding principal and accrued interest of the note.
First Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal	$ 25,000
Second Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal	25,000
Third Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal	$ 25,000
Other Notes Payable One
Debt Instrument [Line Items]
Aggregate principal amount				61,000
Debt Conversion, Original Debt, Amount				$ 244,000
In exchange of notes payable
Debt Instrument [Line Items]
Debt Conversion, Original Debt, Amount					$ 160,000
Conversion of Stock, Shares Issued					78,955
Debt Instrument, Convertible, Conversion Price					$ 2.10
Accrued Interest Converted Into Stock					$ 5,802
Warrants and Rights Outstanding					177,649
Convertible Notes
Debt Instrument [Line Items]
Rate of interest			10.00%
Debt instrument, face amount					163,000
Loss on extinguishment of note payables, net					11,847
Fair value of class of warrant			$ 31,009
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			20,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 4
Debt Instrument, Convertible, Conversion Price			$ 3
Debt Conversion Original Debt Shares Issued			52,457
Original Debt Accrued Interest Converted Into Stock			$ 7,370
Convertible Notes | Lenders [Member]
Debt Instrument [Line Items]
Debt Conversion, Original Debt, Amount			150,000
Convertible Notes | Other Notes Payable One
Debt Instrument [Line Items]
Debt instrument, face amount			$ 250,000
Convertible Notes | Notes Payable Three
Debt Instrument [Line Items]
Debt instrument, face amount					185,000		$ 420,000
Proceeds from Convertible Debt					$ 132,500	$ 197,500

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Commitments and Contingencies Disclosure [Line Items]
Rent Expense	$ 33,000	$ 35,000
Chief Executive Officer Employment Agreements
Commitments and Contingencies Disclosure [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount	$ 407,000

Summary of Warrant Activity (De

Summary of Warrant Activity (Detail) - Warrants	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Number of Warrants
Beginning Balance | shares	1,066,930
Compensatory grants | shares	0
Investor grants | shares	1,268,937
Exercised | shares	(60,831)
Forfeited | shares	0
Ending Balance | shares	2,275,036
Exercisable | shares	2,240,036
Weighted Average Exercise Price
Beginning Balance | $ / shares	$ 7.56	[1]
Compensatory grants | $ / shares	0
Investor grants | $ / shares	4.81
Exercised | $ / shares	3.5
Forfeited | $ / shares	0
Ending Balance | $ / shares	5.85	[1]
Exercisable | $ / shares	$ 5.85
Weighted Average Remaining Life In Years
Outstanding	3 years 8 months 12 days
Exercisable	3 years 8 months 12 days
Aggregate Intrinsic Value
Outstanding | $	$ 153,318
Exercisable | $	$ 153,318
[1]	Excludes the impact of a warrant to purchase 35,000 shares of common stock that has an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability is subject to satisfaction of certain performance criteria which did not occur during the three months ended March 31, 2016.

Black-Scholes Option Pricing Mo

Black-Scholes Option Pricing Model to Stock Option Granted, Weighted Average Assumptions (Detail) - Stock Options	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)		5 years
Expected volatility	124.00%	122.00%
Expected dividends	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.44%	1.22%
Expected term (years)	8 months 1 day
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.47%	1.61%
Expected term (years)	5 years

Information Related to Stock Op

Information Related to Stock Option Expense (Detail) - Stock Options - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 360,994	$ 294,520
Unrecognized expense	$ 2,283,982
Weighted Average Remaining Amortization Period (Years)	2 years
Consulting
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 104,098	96,803
Unrecognized expense	$ 704,231
Weighted Average Remaining Amortization Period (Years)	2 years 1 month 6 days
Research and development
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 107,183	128,432
Unrecognized expense	$ 686,464
Weighted Average Remaining Amortization Period (Years)	2 years
General and administrative
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 149,713	$ 69,285
Unrecognized expense	$ 893,287
Weighted Average Remaining Amortization Period (Years)	2 years

Information Related to Common S

Information Related to Common Stock Award Expense (Detail) - Common Stock Award - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 50,624	$ 76,647
Unrecognized expense	0
Consulting
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	50,624	67,800
Unrecognized expense	0
Research and development
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	0	$ 8,847
Unrecognized expense	$ 0

Stockholders' Deficiency - Addi

Stockholders' Deficiency - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stockholders Equity Note Disclosure [Line Items]
Sales of common stock and warrants for cash	$ 1,618,372	$ 801,000
Warrants aggregate grant date fair value	1,127,283
Proceeds from Warrant Exercises	$ 212,898	$ 0
Warrants to Purchase of Common Stock	1,248,937
Exercised Warrants [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants to purchase common stock	60,831
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.50
Fair Value Adjustment of Warrants	$ 23,448
Warrant One [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants to purchase common stock	444,444
Class of Stock, Warrants or Rights Expiration Term	8 months 12 days
Warrant Two [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants to purchase common stock	400,000
Class of Stock, Warrants or Rights Expiration Term	1 year
Warrant Three [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants to purchase common stock	404,493
Class of Stock, Warrants or Rights Expiration Term	5 years
Exercise Price Dollor Greaterthan 30.00
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted	35,000
Share based compensation shares authorized under stock option plans exercise price	$ 30
Warrants
Stockholders Equity Note Disclosure [Line Items]
Weighted average estimated fair value of stock warrants granted, per share	$ 0.89	$ 3.20
Proceeds from Warrant Exercises	$ 212,898
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4
Class of Warrant or Right, Outstanding	470,085
Warrant Or Right Expense Or Revenue Recognized	$ 5,038
Warrants Issued During Period, Exercise Price	$ 15
Common Stock
Stockholders Equity Note Disclosure [Line Items]
Stock issued (in shares)	404,593
Minimum | Exercised Warrants [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4
Minimum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price	$ 4.50
Estimated Forfeitures Related To Option Grants Annual Rate	0.00%
Maximum | Exercised Warrants [Member]
Stockholders Equity Note Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 15
Maximum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price	$ 5
Estimated Forfeitures Related To Option Grants Annual Rate	5.00%

Subsequent Events- Additional I

Subsequent Events- Additional Information (Detail) - USD ($)	Mar. 04, 2016	Apr. 27, 2016	Apr. 15, 2016	Feb. 15, 2016	Mar. 31, 2016	Mar. 07, 2016	Feb. 18, 2016
Subsequent Event [Line Items]
Debt instrument, interest rate, stated percentage						10.00%
Stock Issued During Period, Value, New Issues					$ 1,618,372
Debt Instrument, Face Amount					163,000	$ 75,000
Debt Instrument, Periodic Payment, Principal	$ 25,000			$ 56,000
Convertible Notes Payable
Subsequent Event [Line Items]
Debt instrument, interest rate, stated percentage							10.00%
Debt Instrument, Face Amount					$ 163,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 4
Investor
Subsequent Event [Line Items]
Warrants Issued During Period, Number of Warrants					56,250
Stock Issued During Period, Shares, New Issues					56,250
Sale of Stock, Price Per Share					$ 4
Stock Issued During Period, Value, New Issues					$ 225,000
Repayments Short Term Advances					$ 28,500
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5
Subsequent Event
Subsequent Event [Line Items]
Debt instrument, interest rate, stated percentage		10.00%
Proceeds from Convertible Debt		$ 65,000
Subsequent Event | Convertible Notes Payable
Subsequent Event [Line Items]
Warrants Issued During Period, Number of Warrants		7,500
Warrants Issued During Period, Exercise Price		$ 4
Stock Issued During Period, Shares, New Issues			6,000
Sale of Stock, Price Per Share		$ 4
Debt Instrument, Face Amount		$ 90,000	$ 148,000
Debt Instrument, Interest Rate, Effective Percentage		10.00%
Debt Instrument, Convertible, Terms of Conversion Feature		The convertible note is payable as follows: (i) $25,000 of the principal and the respective accrued interest on such principal is payable six months from the issuance date (the First Maturity Date), (ii) $20,000 of principal and the respective accrued interest on such principal is payable two weeks following the First Maturity Date, and (iii) $20,000 of principal and the respective accrued interest on such principal is payable one month following the First Maturity Date. Each tranche of principal and the respective accrued interest on such principal is convertible into shares of the Companys common stock at the election of the Company during the period beginning five days prior to each maturity date and ending on the day immediately prior to each maturity date at a conversion price equal to the greater of (a) 60% of the fair value of the Companys stock or (b) $2.00 per share.
Warrant To Purchase Common Stock Issued In Period		10,000
Warrants Vesting Period		5 years
Repayments of Debt			20,000
Debt Instrument, Periodic Payment, Principal			15,000
Debt Instrument, Fee Amount			$ 5,000
Proceeds from Issuance or Sale of Equity, Total		$ 10,000,000